Compare COOK & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | HELP |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.4M | 233.0M |
| IPO Year | 2021 | N/A |
| Metric | COOK | HELP |
|---|---|---|
| Price | $60.95 | $8.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $53.00 | $51.50 |
| AVG Volume (30 Days) | 63.5K | ★ 1.7M |
| Earning Date | 05-11-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $559,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | $56.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $3.76 |
| 52 Week High | $86.59 | $8.55 |
| Indicator | COOK | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 67.87 |
| Support Level | $60.87 | $4.18 |
| Resistance Level | $76.22 | $8.55 |
| Average True Range (ATR) | 5.46 | 0.52 |
| MACD | -1.40 | 0.05 |
| Stochastic Oscillator | 17.95 | 75.00 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.